123 
DR. FREDRICKSON: Dr. Goldstein, and then Dr. Eogness. 
DR. GOLDSTEIN: Just two brief things, one especially on that point 
nunber 9. 
DR. FREDRICKSON: Please move toward the microphone. 
DR. GOLDSTEIN: I think number 9 is a very important point, and we just 
talked about what happens to these strains of vectors which have been made 
already. There are innumerable labs with these. We have now gone through 
1 page of a 20-page critique that we wrote. There are many other differ- 
ences, and I don't know if we have time now. I think Maxine did a very good 
job of going through that. 
'See Appendix A to these Proceedings ] 
DR. SINGER: I am sorry, I understood that page was the target of the 
question. 
DR. FREDRICKSON: I think that was the only target you could have hit. 
DR. GOLDSTEIN: Sure, absolutely, but I just wanted also to make that 
point. 
DR. FREDRICKSON: Well, actually, if I read the documents carefully, 
the two major ones, or the two things not yet dealt with, were the request 
from your group that work with _E. coli be gradually phased out, clearly by 
the end of some period of time, 2 years or so. 
DR. GOLDSTEIN: At least. 
DR. FREDRICKSON: And then you had some issues about quality control 
that are further on in your document. 
DR. GOLDSTEIN: Well, if you turn to page. ... I think it is really the 
second page of the central points in our proposal, which comes right after 
the cover letter, in the summary of the whole thing, and it deals with such 
things as we really feel there is no difference between PI and P2. I even 
question P3 as a real containment facility, but I think it is important at 
least to have some kind of psychological effect on the people working in a 
P3 lab. There are lots of other points like that. 
DR. FREDRICKSON: I think it would be better if we prepared that 
analysis and it were presented in a much more compact way. 
Dr. Eogness? 
DR. EOGNESS: In response to Mr. Eutt's point, I think the committee's 
idea was that we were drafting guidelines to guide future research. The 
[264] 
